The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial

Aims/hypothesis. The purpose of this study is to investigate the cost-effectiveness of simvastatin in diabetic patients, using prospectively collected outcomes data from the Scandinavian Simvastatin Survival Study. Methods. Diabetic patients were identified using two different classifications schemes: Clinical history (diabetic, non-diabetic) and the new American Diabetes Association definition (diabetic, impaired fasting glucose, normal fasting glucose). The analysis is based on prospectively collected data from the trial on hospitalization for cardiovascular problems, study drug utilization and mortality. The incremental cost per life year saved with simvastatin is estimated using costs from Sweden (primary) and other European countries. Results. Hospitalizations for cardiovascular problems were considerably reduced with simvastatin therapy, with the greatest differences in the diabetic subgroups. Reductions in hospitalizations in the diabetic group resulted in substantial hospital cost savings that offset 67 to 76 % of the drug cost (depending on the classification used). For the diabetic patients, the estimates of the cost per life-year gained ranged from 1600 Euros (based on clinical history) to 3200 Euros (based on American Diabetes Association) using Swedish costs. In the other evaluated European countries treatment with simvastatin showed a favourable cost-effectiveness ratio independent of differences in local health care unit costs. Conclusion/interpretation. For all subgroups in the diabetic classification schemes, treatment with simvastatin resulted in estimates of cost per life-year gained that were well within the range generally considered to be cost effective. Based on the Scandinavian Simvastatin Survival Study, simvastatin therapy provides good value for money in both diabetic and non-diabetic patients with cardiovascular disease. [Diabetologia (1999) 42: 1293–1301]

[1]  D Polsky,et al.  Confidence intervals for cost-effectiveness ratios: a comparison of four methods. , 1997, Health economics.

[2]  Gram Jb,et al.  The Scandinavian Simvastatin Survival Study (4S) , 1995 .

[3]  N. Rehnqvist,et al.  Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. , 1985, Journal of the American College of Cardiology.

[4]  B. Efron,et al.  A Leisurely Look at the Bootstrap, the Jackknife, and , 1983 .

[5]  David O. Meltzer,et al.  Editorial: Some reflections on cost‐effectiveness analysis , 1998 .

[6]  A. Zbrozek,et al.  Model of Complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia , 1997, Diabetes Care.

[7]  S. Haffner,et al.  Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. , 1999, Archives of internal medicine.

[8]  J Herlitz,et al.  Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. , 1995, Journal of the American College of Cardiology.

[9]  M. Johannesson,et al.  Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. , 1997, The New England journal of medicine.

[10]  G A Colditz,et al.  The economic costs of non-insulin-dependent diabetes mellitus. , 1989, JAMA.

[11]  B. Jönsson.  Diabetes--the cost of illness and the cost of control. An estimate for Sweden 1978. , 1983, Acta medica Scandinavica. Supplementum.

[12]  M Johannesson,et al.  Some reflections on cost-effectiveness analysis. , 1998, Health economics.

[13]  Terje R Pedersen,et al.  Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.

[14]  Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. , 1996, JAMA.

[15]  G. Thorgeirsson,et al.  Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. , 1996, Circulation.

[16]  N. Ray,et al.  Economic Consequences of Diabetes Mellitus in the U.S. in 1997 , 1998, Diabetes Care.

[17]  B. Hedbäck,et al.  5-year results of a comprehensive rehabilitation programme after myocardial infarction. , 1987, European heart journal.

[18]  J. Herlitz,et al.  Prognosis of Acute Myocardial Infarction in Diabetic and Non‐diabetic Patients , 1993, Diabetic medicine : a journal of the British Diabetic Association.

[19]  B. Jönsson,et al.  Diabetes: the cost of illness in Sweden , 1998, Journal of internal medicine.

[20]  D N Mendelson,et al.  Health care expenditures for people with diabetes mellitus, 1992. , 1994, The Journal of clinical endocrinology and metabolism.

[21]  H Wedel,et al.  Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S) , 1996, European heart journal.